<DOC>
	<DOCNO>NCT00134134</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety efalizumab treat hydradenitis suppurativa , evaluate duration benefit see people respond treatment efalizumab , medication stop .</brief_summary>
	<brief_title>Efficacy Safety Efalizumab Treatment Moderate-Severe Hydradenitis Suppurativa</brief_title>
	<detailed_description>The primary objective study assess efficacy subcutaneously administer efalizumab treatment refractory , severe hydradenitis suppurativa . The secondary objective study assess ability re-establish disease control discontinuation drug allowance relapse disease , well assess safety subcutaneously administer efalizumab treatment refractory , severe hydradenitis suppurativa .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Female 1865 year age Has Hydradenitis Suppurativa ( HS ) involve least 1 area body great equal 12 lesion ; onset disease 6 month great . Failed least 3 month standard conventional therapy antibiotic and/or systemic retinoids Willing use contraception unless childbearing potential Able comply protocol requirement Received within 4 week prior immunosuppressive medication Received treatment within 3 month prior systemic retinoids ( acitretin isotretinoin ) Received high potency ( class I II ) topical corticoid steroid , topical antibiotic , systemic antibiotic , topical immunomodulators ( tacrolimus pimecrolimus ) within 2 week prior baseline visit Received intralesional injection corticosteroid within 4 week prior Received surgical intervention treatment HS Known history HIV seropositivity History untreated active tuberculosis Active infection require systemic antibiotic within 4 week baseline visit History recurrent/chronic infection History malignancy within 5 year baseline visit ( except squamous cell carcinoma basal cell carcinoma ; may enroll treat assessed cure ) . Pregnant breastfeeding Immunocompromised due medical condition Has significant laboratory abnormality Has medical condition may interfere evaluation safety efficacy efalizumab Received efalizumab biologic within last 6 month Taken use investigational drug device within 30 day prior</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>hidradenitis suppurativa</keyword>
	<keyword>efalizumab</keyword>
	<keyword>biologic</keyword>
	<keyword>Raptiva</keyword>
</DOC>